Trevi updates on clinical progress for chronic cough treatment

Trevi Therapeutics (Nasdaq: TRVI) has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Haduvio's unique dual mechanism of action - targeting both kappa opioid receptors as an agonist and mu opioid receptors as an antagonist - allows it to act on both the central and peripheral nervous systems, addressing hypersensitivity in the cough reflex.

This positioning gives it a potentially broad impact on various types of chronic cough, which are often hard to treat and significantly impact patients' quality of life.